Allogeneic Natural Killer Cell Line NK-92 (M.D. Anderson Cancer Center)

异基因自然杀伤细胞系NK-92（M.D. Anderson Cancer Center）

Report date: 2022/12/27 09:22:56

Base Information

Drug NameAllogeneic Natural Killer Cell Line NK-92 (M.D. Anderson Cancer Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative DiseasesCarcinoma, Non-Small-Cell Lung +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of HealthNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative DiseasesCarcinoma, Non-Small-Cell Lung +[16] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A